The Experts below are selected from a list of 168 Experts worldwide ranked by ideXlab platform

Armando J. Villamil - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of tumor volume reduction of nasal carcinomas versus sarcomas in dogs treated with definitive fractionated Megavoltage Radiation: 15 cases (2010-2016).
    BMC research notes, 2018
    Co-Authors: Matthew J. Morgan, David M. Lurie, Armando J. Villamil
    Abstract:

    Local control is a major challenge in treating canine nasal tumors, and cytoreduction following Radiation therapy has been recommended to extend survival and to delay local recurrence. Our objective was to compare the effect of definitive radiotherapy on the tumor volume of intranasal carcinomas compared to sarcomas. We evaluated 15 dogs that received radiotherapy within 1 month of initial CT scan, and post Radiation CT scans performed within 3 months of completing full course definitive Megavoltage Radiation. Tumor reduction volume based on CT scans were obtained and compared between carcinoma and sarcoma groups. The following tumor types were treated; carcinoma (8/15), sarcoma (7/15). The mean nasal tumor size before Radiation therapy was 24.5 cm3 and tumor size after Radiation therapy was 13.5 cm3 resulting in a mean reduction of 55.1% reduction in tumor size for both carcinomas and sarcomas. The carcinoma group displayed a volume reduction of 67.1% (SD ± 16.9) and the sarcoma group displayed a volume reduction of 21.3% (SD ± 39.7). Within the study period carcinomas were more responsive in the reduction of volume than sarcomas with fractionated Megavoltage Radiation.

  • Evaluation of tumor volume reduction of nasal carcinomas versus sarcomas in dogs treated with definitive fractionated Megavoltage Radiation: 15 cases (2010–2016)
    BMC, 2018
    Co-Authors: Matthew J. Morgan, David M. Lurie, Armando J. Villamil
    Abstract:

    Abstract Objective Local control is a major challenge in treating canine nasal tumors, and cytoreduction following Radiation therapy has been recommended to extend survival and to delay local recurrence. Our objective was to compare the effect of definitive radiotherapy on the tumor volume of intranasal carcinomas compared to sarcomas. We evaluated 15 dogs that received radiotherapy within 1 month of initial CT scan, and post Radiation CT scans performed within 3 months of completing full course definitive Megavoltage Radiation. Tumor reduction volume based on CT scans were obtained and compared between carcinoma and sarcoma groups. Results The following tumor types were treated; carcinoma (8/15), sarcoma (7/15). The mean nasal tumor size before Radiation therapy was 24.5 cm3 and tumor size after Radiation therapy was 13.5 cm3 resulting in a mean reduction of 55.1% reduction in tumor size for both carcinomas and sarcomas. The carcinoma group displayed a volume reduction of 67.1% (SD ± 16.9) and the sarcoma group displayed a volume reduction of 21.3% (SD ± 39.7). Within the study period carcinomas were more responsive in the reduction of volume than sarcomas with fractionated Megavoltage Radiation

Nicole C. Northrup - One of the best experts on this subject based on the ideXlab platform.

  • Tolerance Doses of Cutaneous and Mucosal Tissues in Ring-necked Parakeets (Psittacula krameri) for External Beam Megavoltage Radiation
    Journal of Avian Medicine and Surgery, 2009
    Co-Authors: Heather Wilson Barron, Royce E. Roberts, Stephen J. Hernandez-divers, Kenneth S. Latimer, Nicole C. Northrup
    Abstract:

    Currently used dosages for external-beam Megavoltage Radiation therapy in birds have been extrapolated from mammalian patients and often appear to provide inadequate doses of Radiation for effective tumor control. To determine the tolerance doses of cutaneous and mucosal tissues of normal birds in order to provide more effective Radiation treatment for tumors that have been shown to be Radiation responsive in other species, ingluvial mucosa and the skin over the ingluvies of 9 ring-necked parakeets {Psittacula krameri) were irradiated in 4 Gy fractions to a total dose of either 48, 60, or 72 Gy using an isocentric cobalt-60 teletherapy unit. Minimal Radiation-induced epidermal changes were present in the high-dose group histologically. Neither dose-related acute nor chronic Radiation effects could be detected in any group grossly in cutaneous or mucosal tissue over a 9-month period. Radiation doses of 72 Gy in 4-Gy fractions were well tolerated in the small number of ring-necked parakeets in this initial tolerance dose study.

  • Retrospective study of orthovoltage Radiation therapy for nasal tumors in 42 dogs.
    Journal of veterinary internal medicine, 2001
    Co-Authors: Nicole C. Northrup, Sheila M. Etue, David M. Ruslander, Kenneth M. Rassnick, David L. Hutto, Amy Bengtson, William M. Rand, Antony S. Moore
    Abstract:

    Megavoltage Radiation therapy currently is the standard of care for dogs with nasal tumors. Some studies report that surgery and adjunctive orthovoltage Radiation therapy result in longer control of these tumors than does Megavoltage Radiation therapy alone. This study reports less effective control of nasal tumors in dogs treated with surgery and orthovoltage Radiation than previously observed, supporting the superiority of Megavoltage Radiation therapy for these tumors. In addition, this study suggests 2 new prognostic indicators for dogs with nasal tumors and describes toxicity associated with surgery and orthovoltage therapy. Forty-two dogs with nasal tumors were treated with surgical cytoreduction and 48 Gy orthovoltage Radiation therapy administered in twelve 4-Gy fractions. Median survival was 7.4 months. One- and 2-year survival rates were 37% and 17%, respectively. Dogs with facial deformity had shorter survival than those without deformity (P = .005). Dogs with resolution of clinical signs after treatment had longer survival than those with chronic nasal signs (P = .0001). Acute Radiation toxicity was moderate to severe for skin and eye and negligible for oral mucosa. Toxicity healed within 1 month after Radiation therapy. Late toxicity was mild, but 70% of evaluable dogs experienced persistent ocular signs. Only 39% of dogs achieved a disease-free period.

Matthew J. Morgan - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of tumor volume reduction of nasal carcinomas versus sarcomas in dogs treated with definitive fractionated Megavoltage Radiation: 15 cases (2010-2016).
    BMC research notes, 2018
    Co-Authors: Matthew J. Morgan, David M. Lurie, Armando J. Villamil
    Abstract:

    Local control is a major challenge in treating canine nasal tumors, and cytoreduction following Radiation therapy has been recommended to extend survival and to delay local recurrence. Our objective was to compare the effect of definitive radiotherapy on the tumor volume of intranasal carcinomas compared to sarcomas. We evaluated 15 dogs that received radiotherapy within 1 month of initial CT scan, and post Radiation CT scans performed within 3 months of completing full course definitive Megavoltage Radiation. Tumor reduction volume based on CT scans were obtained and compared between carcinoma and sarcoma groups. The following tumor types were treated; carcinoma (8/15), sarcoma (7/15). The mean nasal tumor size before Radiation therapy was 24.5 cm3 and tumor size after Radiation therapy was 13.5 cm3 resulting in a mean reduction of 55.1% reduction in tumor size for both carcinomas and sarcomas. The carcinoma group displayed a volume reduction of 67.1% (SD ± 16.9) and the sarcoma group displayed a volume reduction of 21.3% (SD ± 39.7). Within the study period carcinomas were more responsive in the reduction of volume than sarcomas with fractionated Megavoltage Radiation.

  • Evaluation of tumor volume reduction of nasal carcinomas versus sarcomas in dogs treated with definitive fractionated Megavoltage Radiation: 15 cases (2010–2016)
    BMC, 2018
    Co-Authors: Matthew J. Morgan, David M. Lurie, Armando J. Villamil
    Abstract:

    Abstract Objective Local control is a major challenge in treating canine nasal tumors, and cytoreduction following Radiation therapy has been recommended to extend survival and to delay local recurrence. Our objective was to compare the effect of definitive radiotherapy on the tumor volume of intranasal carcinomas compared to sarcomas. We evaluated 15 dogs that received radiotherapy within 1 month of initial CT scan, and post Radiation CT scans performed within 3 months of completing full course definitive Megavoltage Radiation. Tumor reduction volume based on CT scans were obtained and compared between carcinoma and sarcoma groups. Results The following tumor types were treated; carcinoma (8/15), sarcoma (7/15). The mean nasal tumor size before Radiation therapy was 24.5 cm3 and tumor size after Radiation therapy was 13.5 cm3 resulting in a mean reduction of 55.1% reduction in tumor size for both carcinomas and sarcomas. The carcinoma group displayed a volume reduction of 67.1% (SD ± 16.9) and the sarcoma group displayed a volume reduction of 21.3% (SD ± 39.7). Within the study period carcinomas were more responsive in the reduction of volume than sarcomas with fractionated Megavoltage Radiation

Antony S. Moore - One of the best experts on this subject based on the ideXlab platform.

  • Retrospective study of orthovoltage Radiation therapy for nasal tumors in 42 dogs.
    Journal of veterinary internal medicine, 2001
    Co-Authors: Nicole C. Northrup, Sheila M. Etue, David M. Ruslander, Kenneth M. Rassnick, David L. Hutto, Amy Bengtson, William M. Rand, Antony S. Moore
    Abstract:

    Megavoltage Radiation therapy currently is the standard of care for dogs with nasal tumors. Some studies report that surgery and adjunctive orthovoltage Radiation therapy result in longer control of these tumors than does Megavoltage Radiation therapy alone. This study reports less effective control of nasal tumors in dogs treated with surgery and orthovoltage Radiation than previously observed, supporting the superiority of Megavoltage Radiation therapy for these tumors. In addition, this study suggests 2 new prognostic indicators for dogs with nasal tumors and describes toxicity associated with surgery and orthovoltage therapy. Forty-two dogs with nasal tumors were treated with surgical cytoreduction and 48 Gy orthovoltage Radiation therapy administered in twelve 4-Gy fractions. Median survival was 7.4 months. One- and 2-year survival rates were 37% and 17%, respectively. Dogs with facial deformity had shorter survival than those without deformity (P = .005). Dogs with resolution of clinical signs after treatment had longer survival than those with chronic nasal signs (P = .0001). Acute Radiation toxicity was moderate to severe for skin and eye and negligible for oral mucosa. Toxicity healed within 1 month after Radiation therapy. Late toxicity was mild, but 70% of evaluable dogs experienced persistent ocular signs. Only 39% of dogs achieved a disease-free period.

David M. Lurie - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of tumor volume reduction of nasal carcinomas versus sarcomas in dogs treated with definitive fractionated Megavoltage Radiation: 15 cases (2010-2016).
    BMC research notes, 2018
    Co-Authors: Matthew J. Morgan, David M. Lurie, Armando J. Villamil
    Abstract:

    Local control is a major challenge in treating canine nasal tumors, and cytoreduction following Radiation therapy has been recommended to extend survival and to delay local recurrence. Our objective was to compare the effect of definitive radiotherapy on the tumor volume of intranasal carcinomas compared to sarcomas. We evaluated 15 dogs that received radiotherapy within 1 month of initial CT scan, and post Radiation CT scans performed within 3 months of completing full course definitive Megavoltage Radiation. Tumor reduction volume based on CT scans were obtained and compared between carcinoma and sarcoma groups. The following tumor types were treated; carcinoma (8/15), sarcoma (7/15). The mean nasal tumor size before Radiation therapy was 24.5 cm3 and tumor size after Radiation therapy was 13.5 cm3 resulting in a mean reduction of 55.1% reduction in tumor size for both carcinomas and sarcomas. The carcinoma group displayed a volume reduction of 67.1% (SD ± 16.9) and the sarcoma group displayed a volume reduction of 21.3% (SD ± 39.7). Within the study period carcinomas were more responsive in the reduction of volume than sarcomas with fractionated Megavoltage Radiation.

  • Evaluation of tumor volume reduction of nasal carcinomas versus sarcomas in dogs treated with definitive fractionated Megavoltage Radiation: 15 cases (2010–2016)
    BMC, 2018
    Co-Authors: Matthew J. Morgan, David M. Lurie, Armando J. Villamil
    Abstract:

    Abstract Objective Local control is a major challenge in treating canine nasal tumors, and cytoreduction following Radiation therapy has been recommended to extend survival and to delay local recurrence. Our objective was to compare the effect of definitive radiotherapy on the tumor volume of intranasal carcinomas compared to sarcomas. We evaluated 15 dogs that received radiotherapy within 1 month of initial CT scan, and post Radiation CT scans performed within 3 months of completing full course definitive Megavoltage Radiation. Tumor reduction volume based on CT scans were obtained and compared between carcinoma and sarcoma groups. Results The following tumor types were treated; carcinoma (8/15), sarcoma (7/15). The mean nasal tumor size before Radiation therapy was 24.5 cm3 and tumor size after Radiation therapy was 13.5 cm3 resulting in a mean reduction of 55.1% reduction in tumor size for both carcinomas and sarcomas. The carcinoma group displayed a volume reduction of 67.1% (SD ± 16.9) and the sarcoma group displayed a volume reduction of 21.3% (SD ± 39.7). Within the study period carcinomas were more responsive in the reduction of volume than sarcomas with fractionated Megavoltage Radiation